ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Addex Therapeutics Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026
$2.89+0.13 (+4.71%)
Close on Oct 19, 2026
Addex Therapeutics statistics
Financials through Jun 30, 2026, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Market Cap | CHF 49.30K | CHF 62.39M |
| Enterprise Value | -CHF 718.03K | CHF 27.59M |
| PS Ratio | 1.64 |
Enterprise value
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -23.96 |
Income (trailing twelve months)
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Revenue | CHF 29.97K | |
| Operating Income | -CHF 2.81M | -CHF 69.32M |
| Pretax Income | -CHF 6.84M | -CHF 70.45M |
| EBITDA | -CHF 2.81M | -CHF 69.32M |
| EPS (Diluted) | -0.06 CHF | -1.65 CHF |
Margins
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -9390.8% | |
| Pretax Margin | -22829.9% | |
| EBITDA Margin | -9390.8% | |
| FCF Margin | -7243.8% |
Returns
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -133.0% | -133.0% |
Growth
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -92.6% | |
| EPS Growth (YoY) | -185.7% | |
| Revenue Growth (3Y CAGR) | -72.4% | |
| Revenue Growth (5Y CAGR) | -61.6% |
Balance sheet
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | CHF 767.33K | CHF 27.76M |
| Net Cash (Debt) | CHF 767.33K | CHF 27.76M |
| Net Cash Per Share | 0.01 CHF | 1.03 CHF |
| Working Capital | -CHF 326.37K | CHF 11.40M |
Financial position
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.76 | 2.65 |
| Quick Ratio | 0.58 | 2.21 |
| Interest Coverage | -181.04 | -116.78 |
Cash flow (trailing twelve months)
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -CHF 2.17M | -CHF 51.26M |
| Capital Expenditures | CHF 0 | -CHF 446.00K |
| Free Cash Flow | -CHF 2.17M | -CHF 51.97M |
| FCF Per Share | -0.01 CHF | -1.11 CHF |
Efficiency
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | |
| Revenue Per Employee | CHF 9.99K | |
| Employee Count | 3 | 49 |
Dividends and yields
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| FCF Yield | -4404.1% | -42.3% |
Shares
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 147,832,000 | 50,231,950 |
| Shares Change (YoY) | 9.44% | 10.4% |
| Float | 124,933,000 | 41,812,550 |
| Shares Held by Insiders | 15.5% | 19.3% |
| Shares Held by Institutions | 0.00% |
Taxes
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Income Tax | CHF 0 | CHF 0 |
Scores
| Measure | Addex Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -148.95 | -4.48 |
Calculated by StockData from Addex Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.